DATOS-CAT aims to increase the visibility and semantic impact of the population-based cohorts developed in Catalonia, GCAT|Genomes for life and the COVICAT-CONTENT sub-cohort.

This action aims to improve the processes related to the introduction of phenotypic traits, environmental, genomic and clinical annotations of existing population cohorts, complementing, updating and connecting the available resources and facilitating the exposure and use of existing resources. Specifically, DATOS-CAT aims to increase the visibility and scientific impact of the population-based cohorts developed in Catalonia, GCAT|Genomes for life and the COVICAT-CONTENT sub-cohort, and to contribute to the development of procedures applicable to other cohorts, in particular, the national IMPaCT-Cohort initiative, improving the level of interoperability of their data in the context of the FAIR data ecosystem to facilitate their exploitation and scientific use. The EGA database structure at the genomic level and the development of OpenEHR-compatible standards for working with structured clinical data will be used as a basis for these developments. The proposal contains the elements to align and collaborate with the efforts carried out by the IMPaCT programme and also with the parallel developments of the other Autonomous Communities participating in this initiative. DATOS-CAT seeks to contribute to making the investment made in these cohorts profitable by making them more competitive at a global level by connecting them with direct sources of genomic and clinical information, ultimately resulting in a greater benefit for society.

• Institut de Bioenginyeria de Catalunya (IBEC).
• Barcelona SuperComputing Center - Centro Nacional de Supercomputación (BSC - CNS).
• Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP).
• Fundación Privada Instituto de Salud Global de Barcelona (ISGlobal).
• Hospital Clínic de Barcelona (HCB).
• Fundación Centro de Regulación Genómica (CRG).
• Centro Nacional de Análisis Genómico (CNAG).

Funded by the “Plan Complementario de Biotecnología aplicada a la Salud”, coordinated by the Institut de Bioenginyeria de Catalunya (IBEC) in the framework of the Plan de Recuperación, Transformación y Resiliencia (C17.I1) ‐ Funded by the European Union – NextGenerationEU